In:
médecine/sciences, EDP Sciences, Vol. 35, No. 12 ( 2019-12), p. 949-956
Abstract:
Immunotherapeutic strategies, notably immune checkpoint inhibitors, have become a standard of care for the treatment of advanced cancers, with a growing spectrum of activity. These monoclonal antibodies target the co-inhibitory signals between tumor cells or antigen-presenting cells and T cells, thereby enhancing antitumour T cell activity. However, the occurrence of immune-related adverse events, that can affect all organ-system, represents a major limiting factor to the clinical development of these antibodies. Management of such toxicity requires a close collaboration between oncologists and organ-specialists, by using glucocorticoids and/or other immunosuppressive therapies, with the common objective not alter anti-tumor response.
Type of Medium:
Online Resource
ISSN:
0767-0974
,
1958-5381
DOI:
10.1051/medsci/2019191
Language:
French
Publisher:
EDP Sciences
Publication Date:
2019
detail.hit.zdb_id:
2049442-7
Permalink